Citi raises AstraZeneca target to £186 as tozorakimab prospects improve
Citi raised its target price for AstraZeneca to £186 from £178, citing improved prospects for tozorakimab. The broker increased peak sales forecasts for tozorakimab and SERENA-6, offsetting the removal of SERENA-4. AstraZeneca shares have fallen 15% year-to-date, despite positive clinical results. Citi expects further catalysts, including AVANZAR trial data and efzimfotase alfa results, with a Buy rating maintained.
How this was made
The 30-second read
Why it matters
The target price lift and higher sales forecasts provide a fresh catalyst that could drive short‑term buying interest.
Market read
Analyst upgrade on a large‑cap pharma stock offers a clear trading signal for investors.
What to watch
Potential risks from upcoming trial results (AVANZAR, HICKORY) could temper upside.
Background
Citi's analyst report updates AstraZeneca's valuation based on new clinical data and revised sales forecasts for its pipeline.
Ticker impact
Citi raised its target price for AstraZeneca to £186 and upgraded its sales forecasts for tozorakimab and SERENA-6, providing fresh analyst guidance.
likely upward pressure as investors price in the higher valuation and sales outlook
Analyst target raise is a concrete, time‑sensitive catalyst that can move the stock immediately.
Market effects
Boosts sentiment for the broader pharma/biotech sector as a major player receives upgraded forecasts.
Positive for UK‑listed pharma stocks and ADRs in the US market.
Limited to healthcare investors; no broad macro impact.
Counterpoint
Some investors may view the target raise as already priced in after the recent 15% YTD decline.
Key entities
- companyAstraZeneca PLC
FTSE 100 pharmaceutical company receiving upgraded analyst guidance.
- analystCiti
Investment bank that raised the target price and sales forecasts.
